Loading rounds…
Loading rounds…
Explore funding rounds, the companies behind them and the investors taking part.
| Company | Amount | Round | Sector | Country | Investors | Announced |
|---|---|---|---|---|---|---|
| CT Cyllene TherapeuticsCompany profile Develops DNA medicines for severe neurogenic bladder conditions and other neurological diseases Develops DNA medicines for severe neurogenic bladder conditions and other neurological diseases | €33M | Series CSeries C+ | Biotech | France | Investors | |
| C |
Ranked by rounds participated in · All time
AusperBio, Abcuro, Infinimmune
Epicrispr Biotechnologies, Draig Therapeutics, Triveni Bio
LifeMine Therapeutics, Ollin Biosciences, SonoThera
Leal Therapeutics, Khartis Therapeutics, Vedana Therapeutics
Leal Therapeutics, Amplifica Holdings Group, InduPro
Explore published rounds while the next edition is being prepared.
Transforms how personalized medicines are made with proprietary software and GMP-manufactured excipients
Transforms how personalized medicines are made with proprietary software and GMP-manufactured excipients
| $14M |
| Series A |
| Biotech, Healthtech |
| Finland |
| Investors |
| CT Develops treatments for serious respiratory diseases | $180M | Growth | Biotech | United States | Investors |
| XB Xellar BiosystemsCompany profile Develops 3D human tissue models for drug discovery and testing using Organ-on-a-Chip technology Develops 3D human tissue models for drug discovery and testing using Organ-on-a-Chip technology | $50M | Series A | Biotech | United States | Investors Undisclosed |
| LL Leyden LaboratoriesCompany profile Develops broadly protective antibody-based nasal sprays to prevent infection by influenza and other respiratory viruses Develops broadly protective antibody-based nasal sprays to prevent infection by influenza and other respiratory viruses | €40M | Series B | Biotech | Netherlands | Investors |
| T TissiumCompany profile Develops biomorphic programmable polymers that repair nerves and tissue without stitches Develops biomorphic programmable polymers that repair nerves and tissue without stitches | €30M | Series D+Series C+ | Biotech, Healthtech | France | Investors |
| OB Ollin BiosciencesCompany profile Develops bispecific antibody therapies for retinal vascular diseases including diabetic macular edema and wet AMD Develops bispecific antibody therapies for retinal vascular diseases including diabetic macular edema and wet AMD | $330M | Series B | Biotech | United States | Investors |
| AN Anodyne NanotechCompany profile Develops transdermal microneedle patches delivering GLP-1 and biologic therapeutics without injections Develops transdermal microneedle patches delivering GLP-1 and biologic therapeutics without injections | $12.6M | Series A | Biotech | United States | Investors |
| RB RQ BioCompany profile Develops antibody therapies to prevent seasonal influenza in high-risk and immunocompromised patients Develops antibody therapies to prevent seasonal influenza in high-risk and immunocompromised patients | $115M | Series A | Biotech | United Kingdom | Investors |
| RH Rapalogix HealthCompany profile Develops prescription therapeutics and skincare products for cellular longevity and skin health Develops prescription therapeutics and skincare products for cellular longevity and skin health | $20M | Series A | Biotech | United States | Investors |